Progress, Potential, and Possibilities Podcast / Show

Send us a textMrs. Cheryl Halpern is a Director, Producer, Documentarian, and Co-Founder and Partner of HQ Creative LLC ( https://www.hqcreative.com/ ), an Emmy Award-winning production company and branding agency serving clients around the world.The award winning film '"The Golden Rule: Do Unto Others" produced by HQ Creative and Indonesian award winning company Angel Pictures, began it's theatrical release from September 20-27th, 2024 - https://vimeo.com/904241685/c4fae53c3aMrs. Halpern has a long record of public service in broadcasting, education and international affairs. Mrs. Halpern was nominated to serve on the boards of America’s national and international broadcasting organizations by Presidents George H.W. Bush, Bill Clinton and George W. Bush. In 1990, she was confirmed as a member of the Board for International Broadcasting and as a director of Radio Free Europe/Radio Liberty (RFE/RL). From 1995 through 2002, Mrs. Halpern served on the Broadcasting Board of Governors (BBG) overseeing Voice of America, Radio and TV Marti, RFE/RL, Worldnet, Radio Free Asia and Radio Free Iraq. While serving on the BBG she helped create Radio Sawa, a new American Arabic radio voice to the Middle East. In August, 2002, she was confirmed to serve as a director of the Corporation for Public Broadcasting (CPB). She was subsequently elected by her peers as chairman of the CPB and served the two-term limit. In addition, Mrs. Halpern was a Public Delegate of the United States, with the rank of Ambassador, to the 63rd Session of the General Assembly of the United Nations. During the Obama Administration she has been a member of the U.S. Holocaust Memorial Council.Mrs. Halpern has also chaired the character education program of the Words Can Heal organization. This national campaign to curb gossip, fight verbal violence and promote the healing powers of ethical speech received bipartisan support from the US Congress as well as from diverse ethnic and religious groups. In her capacity as a Presidential-appointed US delegate to the Organization for Security and Co-operation in Europe (OSCE) Conference on Anti-Semitism, Mrs. Halpern addressed the plenary on children’s programming and textbook development. As the current chairman of the Queen of Sheba Foundation Mrs. Halpern has partnered in the development of “Midako”, an illustrated children’s book publishing initiative to promote literacy in Ethiopia.As a documentarian, Mrs. Halpern has produced several commissioned as well as independently produced documentaries. Most notably, the government of Ethiopia commissioned Mrs. Halpern and her HQ Creative LLC team to produce a memorial documentary to the late Prime Minister, Meles Zenawi. A special tribute to Prime Minister Meles Zenawi was also produced for screening at the 50th Anniversary of the African Union.Mrs. Halpern’s independently produced documentaries have provided compelling historical and cultural information to her audiences. Her films have focused on embodying the spirit of achievement and thereby providing positive visual images and messages for all; regardless of age, gender or ethnicity. Mrs. Halpern’s documentaries have received awards from film festivals around the world. They have been screened by colleges and universities and have been included in Museum exhibits and archive collections.#TheGoldenRule #DoUntoOthers #CherylHalpern #EthicOfReciprocity #Peace #Coexistence #Interfaith #Humanitarian #Tolerance #Religion #EphraimIsaac #ImamShamsiAli #Ghandi  #Documentary #Indonesia #Ethiopia #Israel #Nigeria  #CorporationForPublicBroadcasting #HerRoyalMajestyQueenAngeliqueMonet  #HolocaustMemorialCouncil #OrganizationForSecurityAndCooperationInEuropSupport the show

Send us a textDr. Richard Scranton, M.D., M.P.H., is the President of Global Product Development and the Chief Medical Officer of Lyndra Therapeutics ( https://lyndra.com/ ), a company pioneering long-acting oral therapies, designed to deliver medicine for up to a week or longer in an oral form. Dr. Scranton is responsible for advancing the company's proprietary LYNX™ drug delivery platform ( https://lyndra.com/platform/ ) and evolving and overseeing portfolio strategy, current and future product development from preclinical through commercialization, and external partnerships and alliances. Dr. Scranton has 20+ years of expertise in pharmaco-epidemiologic research, clinical epidemiology, health services research and clinical trials research.Prior to joining Lyndra, Dr. Scranton held roles with increasing responsibility at Pacira Pharmaceuticals, including Chief Medical Officer, where he led the global development and advancement of their non-opioid long-lasting injectable local anesthetic. Dr. Scranton also served as Chief Medical Officer at VeroScience, where his responsibilities included all aspects of clinical development, regulatory and pharmacovigilance of their investigational drugs in the metabolic disease and immunological domains. Dr. Scranton also has served as instructor in medicine at Harvard Medical School and associate physician in the division of aging at Brigham and Women’s Hospital, associate medical director and research consultant for Phase V Technologies, assistant clinical professor of medicine at the Uniformed Services University of the Health Sciences and a senior research fellow at the Massachusetts Veterans Administration Epidemiology, Research and Information Center (MAVERIC).Dr. Scranton earned a Bachelor of Arts from the University of Tennessee and a Doctor of Medicine from the Quillen College of Medicine at Eastern Tennessee State University. He completed his internship and residency in internal medicine at the Naval Medical Center in Portsmouth, Va, and served as chief resident. He completed his Harvard General Medicine Fellowship and received a Master of Public Health from the Harvard School of Public Health. #RichardScranton #LyndraTherapeutics #LongActing #OralTherapies #Risperidone #Pharmacoepidemiology #MedicationAdherence #RobertLanger #BiochemicalEngineering #Schizophrenia #OpioidUseDisorder #PregnancyPrevention #Pharmacokinetics #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #ViralPodcast  #STEM #Innovation #Technology #Science #ResearchSupport the show

Send us a textDr. Rasha Hammamieh, Ph.D. is Director, Medical Readiness Systems Biology (MRSB), at the Walter Reed Army Institute of Research ( https://wrair.health.mil/Biomedical-Research/Center-for-Military-Psychiatry-and-Neuroscience/Medical-Readiness-Systems-Biology/ ) where her lab seeks to apply integrative biology approaches to diseases of military relevance, such as post-traumatic stress disorder, traumatic brain injury pain and biological responses to polytrauma and austere environments (heat stress, acute mountain sickness, hypoxia, radiation and microgravity). The majority of Dr. Hammamieh’s work aims to provide an understanding and develop countermeasures for diseases and injuries in support of service members.  Currently, the MRSB lab is assessing the effect of spaceflight conditions onboard the International Space Station (ISS) on health and disease, and Dr. Hammamieh’s team has multiple biological investigations sponsored by the ISS National Laboratory examining the effects of microgravity on the healing of bone and skin wounds. Dr. Hammamieh has authored and co-authored more than 145 publications, three book chapters, and is a co-inventor of the patent “Biomarkers of Immune Dysfunction in Response to Chronic Stress.” Dr. Hammamieh earned a pharmacy degree from Damascus University, Damascus, Syria and a Ph.D. in Biochemistry from Georgetown University.#RashaHammamieh #MedicalReadiness #SystemsBiology #WalterReedArmyInstituteOfResearch #MilitaryPsychiatry  #PTSD #Neuroscience #IntegrativeBiology #Military #PostTraumaticStressDisorder #TraumaticBrainInjury #Polytrauma #AustereEnvironments #HeatStress #AcuteMountainSickness #Hypoxia #Radiation #Microgravity #EpigeneticClocks #SpaceBiology #InfectiousDiseases #Sepsis #Toxicology #Radiobiology #InternationalSpaceStation #ISS #Biomarkers #ImmuneDysfunction #ChronicStress #Aging  #Damascus #Syria #Georgetown #NASA #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #ViralPodcast  #STEM #Innovation #Technology #Science #ResearchSupport the show

Send us a textDr. Francis S. Collins, M.D., Ph.D., ( https://www.francisscollins.com/ ) is the former Director of the U.S. National Institutes of Health (NIH), where as the longest serving director of NIH (spanning 12 years and three presidencies) he oversaw the work of the largest supporter of biomedical research in the world, from basic to clinical research.  Dr. Collins continues to serve as NIH Distinguished Investigator, Center for Precision Health Research, at the National Human Genome Research Institute ( NHGRI - https://irp.nih.gov/pi/francis-collins ).Dr. Collins is a physician-geneticist noted for his landmark discoveries of disease genes and his leadership of the international Human Genome Project, which culminated in April 2003 with the completion of a finished sequence of the human DNA instruction book. He served as director of the National Human Genome Research Institute at the NIH from 1993-2008.Dr. Collins' research laboratory has discovered a number of important genes, including those responsible for cystic fibrosis, neurofibromatosis, Huntington's disease, a familial endocrine cancer syndrome, and most recently, genes for type 2 diabetes, and the gene that causes Hutchinson-Gilford progeria syndrome, a rare condition that causes premature aging.Dr. Collins received a B.S. in chemistry from the University of Virginia, a Ph.D. in physical chemistry from Yale University, and an M.D. with honors from the University of North Carolina at Chapel Hill. Prior to coming to the NIH in 1993, he spent nine years on the faculty of the University of Michigan, where he was a Howard Hughes Medical Institute investigator. He is an elected member of the Institute of Medicine and the National Academy of Sciences. Dr. Collins was awarded the Presidential Medal of Freedom in November 2007 and the National Medal of Science in 2009.Dr. Collins also founded and served as President of The BioLogos Foundation ( https://biologos.org/ ), which promotes discourse on the relationship between science and religion.Dr. Collins is also an accomplished author with many available titles including The Language of Life: DNA and the Revolution in Personalized Medicine, The Language of God: A Scientist Presents Evidence for Belief, Music and Mind: Harnessing the Arts for Health and Wellness, and a new book coming out The Road to Wisdom: On Truth, Science, Faith, and Trust - Sep 17, 2024 ( https://www.amazon.com/Road-Wisdom-Truth-Science-Faith/dp/0316576301 ).#FrancisCollins #NationalInstitutesOfHealth #HumanGenomeProject #NIH #Progeria #Cancer #Diabetes #Repurposing #Wisdom #Faith #Truth #Trust #BioLogosFoundation #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #ViralPodcast  #STEM #Innovation #Technology #Science #ResearchSupport the show

Send us a textDr. Benjamin L. Oakes, Ph.D., is Co-Founder, President, and Chief Executive Officer at Scribe Therapeutics ( https://www.scribetx.com/ ), a molecular engineering company focused on creating best-in-class CRISPR-based therapies that permanently treat the underlying cause of disease. Previously, as an Innovative Genomics Institute Entrepreneurial Fellow, Dr. Oakes focused on the holistic engineering of genome editing technologies to build novel genome editing molecules.Dr. Oakes has contributed to over 35 publications and patent applications across synthetic biology, molecular engineering, CRISPR, and zinc finger-based genetic modification. Dr. Oakes has been named to the MIT Technology Review 35 Innovators Under 35, San Francisco Business Times 40 Under 40, Endpoints 20 Under 40 in Biopharma, Business Insider 30 Under 40 Transforming Healthcare, and the Biocom Life Sciences Catalyst Awards. He received a Ph.D. in Molecular and Cellular Biology from the University of California, Berkeley, in 2017, where he worked in the Doudna Lab and Savage Lab developing CRISPR-Cas9 molecules with enhanced characteristics. Two such projects resulted in distinct versions of synthetic sensing systems that can modify nucleic acids only when triggered by external stimuli, and have found use in both research and pragmatically applied technologies.Prior to his Ph.D., Dr. Oakes received his B.A. in the fields of Philosophy and Neurobiology and worked as a researcher applying unbiased, combinatorial evolution methods to build tens of thousands of “version one” genome editing tools, providing an open source framework for scientists and medical professionals to modify the genome before the discovery of CRISPR technology.#BenjaminOakes #ScribeTherapeutics #MolecularEngineering #CRISPR #InnovativeGenomicsInstitute #JenniferDoudna #MolecularBiology #UniversityOfCalifornia #Berkeley #SyntheticBiology #ZincFingerNucleases #Optogenetics #EmmanuelleCharpentier  #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #STEM #Innovation #Technology #Science #ResearchSupport the show

Send us a textBen Zimmer is CEO of Priovant Therapeutics ( https://www.priovanttx.com/ ), a clinical-stage biotechnology company focused on delivering novel therapies for autoimmune diseases associated with the greatest morbidity and mortality. Priovant is developing oral brepocitinib, a potential first-in-class dual inhibitor of TYK2 and JAK1, across multiple severe autoimmune indications, unlocking new treatment options for patients who are underserved by existing therapies.Ben joined Priovant from Roivant, where he was a member of the founding team in early 2015 and held multiple leadership roles across the organization, including President, Roivant Health, Chief Operating Officer, and Head, Public Affairs. As President, Roivant Health, Ben led and oversaw the launch of Roivant's Chinese biopharmaceutical subsidiaries, healthcare technology companies (including Datavant), and computationally powered drug discovery platform (including VantAI). Earlier in his career, Ben was a consultant at McKinsey & Co and co-founded and led a public policy non-profit. He holds a BA magna cum laude from Harvard College and a JD from Yale Law School.#BenZimmer #PriovantTherapeutics #AutoimmuneDiseases #Brepocitinib #TYK2 #JAK1 #Dermatomyositis #NonInfectiousUveitis #Pfizer #Roivant #VivekRamaswamy #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #STEM #Innovation #Technology #Science #ResearchSupport the show

Send us a textRocky Batzel is CEO of SnapSlide ( https://www.snapslide.com/ ), a company that recently introduced to the market the First Child-Resistant Closure with Single-Handed Opening for RX and OTC medication Bottles. This patented solution, of which Mr. Batzell is the inventor, is focused on bringing life-changing potential for over 60 million Americans with physical limitations, finally addressing the vital yet widely overlooked aspect of inclusivity – namely medication accessibility.  Mr. Batzell earned a bachelor’s degree in biology from Marywood University in Pennsylvania, and while enrolled in medical school, he noticed his grandmother struggling with a traditional, "push-and-twist", child-resistant cap on her prescription bottle. That inspirational moment led him to pivot his career into the world of entrepreneurship, and he set out to design the very first prototype of what would eventually become SnapSlide. After securing patent protection, Mr. Batzell ultimately formed a company around his groundbreaking innovation. As the company’s CEO, he is dedicated to advancing engineering, diversifying applications, and leading SnapSlide’s mission to bring this adaptive solution to those who need it most.#RockyBatzel #SnapSlide #ChildResistantClosure #SingleHandedOpening #RX #OTC #MedicationBottles #Arthritis #Fibromyalgia #MultipleSclerosis #ParkinsonsDisease #Amputation #Stroke #Paralysis #BirthDefects #Disabilities #MedicationAdherence #Compliance  #Pharmacy #Agetech #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #STEM #Innovation #Technology #Science #ResearchSupport the show

Send us a textDr. Angie Burnett, Ph.D. is Program Director at the Advanced Research and Invention Agency ( ARIA - https://www.aria.org.uk/ ), a UK organization created by an Act of Parliament, and sponsored by the Department for Science, Innovation, and Technology, to fund projects across a full spectrum of R&D disciplines, approaches, and institutions, per the ARIA mission statement to “Look beyond what exists today to the breakthroughs we’ll need tomorrow”.Prior to this role, Dr. Burnett was a Research Associate in the Department of Plant Sciences, and a former David MacKay Research Associate at Darwin College and Cambridge Zero where her work focused on understanding the response of maize plants to high light and cold temperature stresses, and the genetic basis for stress tolerance, so that breeders can produce plants which are better able to withstand environmental stress.Dr. Burnett’s background is in plant physiology. She holds a BA from the University of Cambridge and a PhD from the University of Sheffield, where she was awarded the inaugural PhD studentship from the Society for Experimental Biology. Before commencing her role at the University of Cambridge, she worked as a postdoctoral research associate at Brookhaven National Laboratory in the USA and as a Consultant at the Food and Agriculture Organization of the United Nations in Italy.Important Episode Links"Programmable Plants" Opportunity Space - https://www.aria.org.uk/wp-content/uploads/2024/02/ARIA-Programmable-Plants-v1.pdf"Synthetic Plants For A Sustainable Future" Program Thesis - https://www.aria.org.uk/wp-content/uploads/2024/06/ARIA-Synthetic-plants-for-a-sustainable-future.pdf#AngieBurnett #AdvancedResearchAndInventionAgency #ARIA #SyntheticPlants #PlantPhysiology #FoodSecurity #CropStress #CropYield #PlantBiotechnology#Genetics #PlantEnvironmentInteractions #ClimateChange #DepartmentForScienceInnovationAndTechnology #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #STEM #Innovation #Technology #Science #ResearchSupport the show

Send us a textDr. Deborah Sesok-Pizzini, MD, MBA, is Chief Medical Officer And Senior Vice President, Labcorp Diagnostics, and Global Head of Quality And Discipline Director, Immunohematology, Labcorp ( https://www.labcorp.com/deborah-sesok-pizzini-md-mba ), where she is involved in furthering the company's initiatives to enhance the patient experience, enable health provider decisions and develop innovative testing solutions.Dr. Sesok-Pizzini joined Labcorp with over two decades of experience in healthcare, holding multiple appointments with The Children’s Hospital of Philadelphia, including Patient Safety Officer, Chief of the Division of Transfusion Medicine and Vice-Chief of Pathology and Laboratory Medicine. She was also a professor of clinical pathology and laboratory medicine at the Perelman School of Medicine at the University of Pennsylvania in Philadelphia, PA.Dr. Sesok-Pizzini earned her medical degree from the Penn State College of Medicine and did her residency and fellowship at The University of Pennsylvania’s Perelman School of Medicine. She also graduated from Villanova University, with a Master of Business Administration degree with a concentration in finance.Dr. Sesok-Pizzini holds certifications in clinical pathology and blood bank and transfusion medicine. She is a member of the College of American Pathology, the American Society of Clinical Pathology, and the Association for the Advancement of Blood and Biotherapies. She is a board member of the Intersociety Council for Pathology Information and serves as an adjunct professor with the University of Pennsylvania’s Perelman School of Medicine.#DeborahSesokPizzini #ChiefMedicalOfficer #Labcorp #Diagnostics #Immunohematology #ChildrensHospitalOfPhiladelphia #CHOP  #TransfusionMedicine #Pathology #LaboratoryMedicine #PerelmanSchoolOfMedicine #UniversityOfPennsylvania #Penn #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #ViralPodcast #STEM #Innovation #Technology #Science #ResearchSupport the show

Send us a textVid Desai is Chief Information Officer, Office of Digital Transformation (ODT), at the U.S. Food And Drug Administration (FDA), where he sets and leads the agency’s Information Technology (IT) strategy, as well as the agency’s enterprise IT, data management, and cybersecurity. (https://www.fda.gov/about-fda/fda-organization/vid-desai)The ODT oversees the overall FDA IT spend of close to $1Bn and a staff of around 2,500 employees and contractors. In this capacity, Mr. Desai was recently named to the Forbes CIO Next List 2023 and was the only federal CIO to receive this honor. He was also selected as a WashingtonExec Top Government IT Leaders to watch in 2023, in additional to multiple agency and industry awards. Prior to being named CIO, Mr. Desai served as the FDA’s Chief Technology Officer, overseeing day-to-day technology operations as the leader of the Office of Information Management and Information Technology.Mr. Desai is a seasoned, nationally recognized technology leader with over 35 years of experience in the IT field, and healthcare and life sciences industries. He has previous experience working for large pharmaceutical and medical device companies, and clinical research organizations.Prior to joining the FDA in 2019, Mr. Desai held the CIO role at Vyaire Medical, a respiratory medical device company formed from a divestiture from Becton Dickinson. He was CIO at Endochoice, a GI device and services provider, and Lake Region Medical, which was acquired by Greatbach to form Integer, a medical device, outsource manufacturer. His previous experience includes IT leadership roles with large CRO and pharmaceuticals, including Quintiles Transnational, where he served as executive director, Global IT Infrastructure. Prior to Quintiles, Mr. Desai held several leadership positions of increasing responsibility with GlaxoSmithKline. He started his career in IT as a software engineer at Digital Equipment Corporation in Reading, U.K.Mr. Desai holds a Bachelor of Science in Computer Science (first class with honors) from Royal Holloway College, University of London.Important Episode Links FDA’s Technology Modernization Action Plan (TMAP) - https://www.fda.gov/media/130883/downloadFDA's Data Modernization Action Plan (DMAP) -https://www.fda.gov/media/143627/download?attachmentFDA's Cybersecurity Modernization Action Planhttps://www.fda.gov/media/163086/download?attachment#VidDesai #ChiefInformationOfficer #OfficeOfDigitalTransformation #FoodAndDrugAdministration #FDA #InformationTechnology #ZeroTrust #ArtificialIntelligence #QuantumComputing #IT #Cybersecurity #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #ViralPodcast #STEM #Innovation #Technology #Science #ResearchSupport the show